Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q4653190> ?p ?o }
Showing triples 1 to 31 of
31
with 100 triples per page.
- Q4653190 subject Q7334131.
- Q4653190 subject Q7335338.
- Q4653190 subject Q8431759.
- Q4653190 subject Q8761816.
- Q4653190 subject Q8802906.
- Q4653190 abstract "Brigatinib (previously known as AP26113) is an investigational small-molecule targeted cancer therapy being developed by ARIAD Pharmaceuticals, Inc. Brigatinib has exhibited activity as a potent dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). ARIAD has begun a Phase 1/2 clinical trial of brigatinib based on cancer patients’ molecular diagnoses in September 2011. ALK was first identified as a chromosomal rearrangement in anaplastic large cell lymphoma (ALCL). Genetic studies indicate that abnormal expression of ALK is a key driver of certain types of non-small cell lung cancer (NSCLC) and neuroblastomas, as well as ALCL. Since ALK is generally not expressed in normal adult tissues, it represents a highly promising molecular target for cancer therapy.Epidermal growth factor receptor (EGFR) is another validated target in NSCLC. Additionally, the T790M “gatekeeper” mutation is linked in approximately 50 percent of patients who grow resistant to first-generation EGFR inhibitors. While second-generation EGFR inhibitors are in development, clinical efficacy has been limited due to toxicity thought to be associated with inhibiting the native (endogenous or unmutated) EGFR. A therapy designed to target EGFR, the T790M mutation but avoiding inhibition of native EGFR is another promising molecular target for cancer therapy.".
- Q4653190 iupacName "5-Chloro-N2-{4-[4-(dimethylamino)-1-piperidinyl]-2-methoxyphenyl}-N4-[2-(dimethylphosphoryl)phenyl]-2,4-pyrimidinediamine".
- Q4653190 thumbnail Brigatinib.svg?width=300.
- Q4653190 wikiPageWikiLink Q14865565.
- Q4653190 wikiPageWikiLink Q1988322.
- Q4653190 wikiPageWikiLink Q2198549.
- Q4653190 wikiPageWikiLink Q3658562.
- Q4653190 wikiPageWikiLink Q4652380.
- Q4653190 wikiPageWikiLink Q4653724.
- Q4653190 wikiPageWikiLink Q486090.
- Q4653190 wikiPageWikiLink Q492646.
- Q4653190 wikiPageWikiLink Q7334131.
- Q4653190 wikiPageWikiLink Q7335338.
- Q4653190 wikiPageWikiLink Q8431759.
- Q4653190 wikiPageWikiLink Q8761816.
- Q4653190 wikiPageWikiLink Q8802906.
- Q4653190 wikiPageWikiLink Q938205.
- Q4653190 iupacname "5".
- Q4653190 type ChemicalCompound.
- Q4653190 type ChemicalSubstance.
- Q4653190 type ChemicalObject.
- Q4653190 type Thing.
- Q4653190 type Q11173.
- Q4653190 comment "Brigatinib (previously known as AP26113) is an investigational small-molecule targeted cancer therapy being developed by ARIAD Pharmaceuticals, Inc. Brigatinib has exhibited activity as a potent dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). ARIAD has begun a Phase 1/2 clinical trial of brigatinib based on cancer patients’ molecular diagnoses in September 2011.".
- Q4653190 label "Brigatinib".
- Q4653190 depiction Brigatinib.svg.